

# Invitation to presentation of Xbrane Biopharma's interim report January – March 2022 on May 5, 2022.

**Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Thursday, May 5, 2022, at 11.00 a.m. CET. Xbrane will publish the company's interim report January – March 2022, on Thursday, May 5, 2022, at 8.00 a.m. CET.**

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – March 2022, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

## Web link:

[Xbrane interim report January - March 2022 presentation](#)

## Confirmation Code: 304 98 28

Standard international: +44 (0) 2071 928 338

UK (Local): +44 (0) 844 481 97 52

UK (Tollfree): +44 (0) 800 279 66 19

Sweden (Local): +46 (0) 856 618 467

Sweden (TollFree): +46 (0) 200 125 160

US (Local): +1 646 741 31 67

US (TollFree): +1 877 870 91 35

## Contacts

Martin Åmark, CEO

M: +46 76 309 37 77

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

Press Release  
02 May 2022 14:00:00 CEST



---

## Attachments

---

[Invitation to presentation of Xbrane Biopharma's interim report January – March 2022 on May 5, 2022.](#)